Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
| Image |  |
|---|---|
| Description | scientific article published on 7 April 2016 |
| Author/s | |
| Publication date | April 7, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |